@article{5ead01ee43d4433dbed7fd5310b98115,
title = "Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer?",
keywords = "NSCLC, SCLC, Immune checkpoint inhibitors, Radiotherapy, SAFETY EVALUATION, THERAPY",
author = "Hendriks, {Lizza E. L.} and Jessica Menis and {De Ruysscher}, {Dirk K. M.} and Martin Reck",
note = "Funding Information: Disclosure: Dr. Hendriks: none related to the current manuscript; outside of the current manuscript?research funding: Roche, Boehringer Ingelheim, and AstraZeneca (all institutions); advisory board: Boehringer, BMS, Lilly, Roche, and Pfizer (all institutions); speaker: MSD; travel/conference reimbursement: Roche, BMS (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Quadia (self). Dr. Menis: none related to the current manuscript; outside of the current manuscript?advisory: BMS, Boehringer Ingelheim, MSD, and Roche; travel: Boehringer Ingelheim, Ipsen, MSD, BMS, and AstraZeneca. Dr De Ruysscher?research funding: Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Philips, and Olink (all institutions); advisory board: Bristol-Myers Squibb, Celgene, Merck/Pfizer, Roche/Genentech, AstraZeneca, MSD, and Seattle Genetics (all institutions). Dr. Reck: none related to the current manuscript; outside of the current manuscript: honoraria for lectures and consultancy from Roche, AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Lilly, MSD, Merck, Novartis, Pfizer, and Amgen.",
year = "2020",
month = feb,
doi = "10.1016/j.jtho.2019.12.106",
language = "English",
volume = "15",
pages = "166--169",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier Science",
number = "2",
}